Navigation Links
Researchers Design Promising Cancer Drug
Date:3/7/2008

It activates p53 tumor-suppressor function without causing DNA damage

FRIDAY, March 7 (HealthDay News) -- A drug that targets a protein interaction involved in many types of cancer has been created by University of Michigan researchers.

In cell cultures, the small-molecule inhibitor MI-219 was highly effective at preventing the tumor-suppressor function of the protein p53 from being blocked in the presence of a protein called MDM2.

In animals with human cancer, MI-219 completely inhibited tumor growth and appeared to cause no severe side effects.

"For more than 10 years, scientists have searched for ways to block p53 inhibition, but with little success. Our study clearly shows that this can be done," study author Shaomeng Wang, a professor of medicine at the U-M Medical School and co-director of the molecular therapeutics program at the U-M Comprehensive Cancer Center, said in a prepared statement.

The research was published online this week in the Proceedings of the National Academy of Sciences.

Clinical trials of the drug could begin by the end of 2008. If the drug proves safe and effective in humans, it could potentially be used to treat many kinds of cancer, according to the researchers.

In almost all types of human cancer, p53 is inactivated. About half the time, this is because the protein MDM2 binds to p53 and inhibits the tumor-suppressor function of p53. In other cases, p53 dysfunction is due to a missing or mutated gene.

"Many traditional cancer drugs also activate p53, but they do so by causing DNA damage. They kill not only tumor cells but also normal cells, thus having severe side effects. MI-219 is unique in that it is designed to activate p53 without causing DNA damage, specifically killing tumor cells," Wang said.

The University of Michigan has filed a patent application for MI-219 and its related molecules. The technology has been licensed by Ascenta Therapeutics Inc., which helped fund the study. Wang is a scientific founder of Ascenta, serves as its chief scientific adviser, and is the principal investigator on a research contract from Ascenta to U-M.

More information

The National Cancer Institute has more about cancer.



-- Robert Preidt



SOURCE: University of Michigan, news release, March 3, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Case Western Reserve University researchers identify colorectal cancer gene
2. On a roll: MIT researchers devise new cell-sorting system
3. Einstein researchers genetically engineer immune cells into potent weapons for battling HIV
4. Researchers control growth rate of replacement blood vessels, tissues
5. New protein discovery helps researchers understand autoimmune diseases
6. UF researchers warn parents about dangers of childhood foot burns
7. UCLA researchers find blood stem cells originate and are nurtured in the placenta
8. UCSF researchers validate new model for breast cancer risk assessment in multiple ethnic groups
9. Einstein researchers discover gene mutations linked to longer lifespans
10. U-M researchers ID promising new cancer drug
11. Researchers identify new genetic marker for breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers Design Promising Cancer Drug
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The American ... to become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer ... Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. ...
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
Breaking Medicine Technology: